Capcom Reveals Dragon’s Dogma 2 Scheduled to Launch March 22, 2024!
Capcom Co., Ltd. (TOKYO:9697) today announced that Dragon’s Dogma 2, the latest game in the Dragon’s Dogma series, is scheduled to be released on March 22, 2024. With the launch of Dragon’s Dogma 2, Capcom closes out a stellar year of major title releases for its 2023 fiscal year.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231128898951/en/
Dragon's Dogma 2 is a single player, narrative driven action-RPG and the latest title in the Dragon’s Dogma series. The game features intricately crafted, gorgeous visuals powered by Capcom’s proprietary RE ENGINE that elevate its unique gameplay experience to provide a truly immersive fantasy world sure to delight both newcomers as well as long-time fans of the series. (Graphic: Business Wire)
Dragon’s Dogma 2 is the latest title in the series, and the first mainline entry since the original Dragon’s Dogma was released in 2012. The game is being developed on Capcom’s proprietary RE ENGINE to provide an all-too-real world of fantasy, intricately crafted with gorgeous visuals. Moreover, the game provides an even higher degree of freedom in its action than its predecessor, while providing players with a taste of adventuring in a group when playing solo thanks to AI-controlled pawn characters that act as travelling companions. Dragon’s Dogma 2 is currently in development and aims to deliver an experience that satisfies both newcomers as well as long-time fans. Further, excitement for the title was exemplified at Tokyo Game Show 2023, held in September 2023, where the game was selected for an award in the Future Division, which recognizes the most anticipated upcoming titles during the show.
Capcom remains firmly committed to satisfying the expectations of all stakeholders by leveraging its industry-leading game development capabilities in order to create highly entertaining gameplay experiences.
ABOUT Dragon’s Dogma
The Dragon’s Dogma series consists of action games in a fantasy setting where players adventure in an expansive open world of swords and magic. Since the release of the first game in 2012, the series garnered praise worldwide for gameplay features such as its “pawn” adventure companions who can carry out actions on their own, leading the series to over 7.9 million units sold cumulatively (as of September 30, 2023).
More information about Dragon’s Dogma 2 can be found at https://www.dragonsdogma.com/2/
Capcom is a leading worldwide developer, publisher and distributor of interactive entertainment for game consoles, PCs, handheld and wireless devices. Founded in 1983, the company has created hundreds of games, including groundbreaking franchises Resident Evil™, Monster Hunter™, Street Fighter™, Mega Man™, Devil May Cry™ and Ace Attorney™. Capcom maintains operations in the U.S., U.K., Germany, France, Hong Kong, Taiwan, Singapore and Tokyo, with corporate headquarters located in Osaka, Japan. More information about Capcom can be found at https://www.capcom.co.jp/ir/english/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
Capcom Public Relations & Investor Relations Section
About Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeiGene Receives Positive CHMP Opinion for Tislelizumab as Treatment for Non-Small Cell Lung Cancer26.2.2024 11:00:00 CET | Press release
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a positive opinion recommending approval of tislelizumab as a treatment for non-small cell lung cancer (NSCLC) across three indications: In combination with carboplatin and either paclitaxel or nab-paclitaxel for the first-line treatment of adult patients with squamous NSCLC who have locally advanced NSCLC and are not candidates for surgical resection or platinum-based chemoradiation, or metastatic NSCLC. In combination with pemetrexed and platinum-containing chemotherapy for the first-line treatment of adult patients with non-squamous NSCLC whose tumors have PD-L1 expression on ≥50% of tumor cells with no EGFR or ALK positive mutations and who have locally advanced NSCLC and are not candidates for surgical resection or platinum-based chemoradiation, or metastatic NSCLC. As monothe
GIGABYTE Ignites AI and 5G Visions at MWC 2024, Highlighting New Supercomputers, Edge AI and Sustainable IT Upgrades26.2.2024 09:30:00 CET | Press release
GIGABYTE Technology, an IT pioneer advancing global industries through cloud and AI computing systems, is presenting innovative enterprise computing solutions at MWC 2024, featuring trailblazing servers, green computing solutions, and edge AI technologies, under the theme "Future of COMPUTING." These advancements usher in new possibilities for agile and sustainable IT strategies, enabling industries to harness real-time intelligence across hyperconnected data centers, cloud, edge, and devices, resulting in enhanced efficiency, cost-effectiveness, and competitive advantages, all propelled by the synergies of 5G and AI technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240226750501/en/ GIGABYTE Ignites AI and 5G Visions at MWC 2024, Highlighting New Supercomputers, Edge AI and Sustainable IT Upgrades (Photo: Business Wire) The New Supercomputer Unveiled GIGABYTE presents G593-ZX1/ZX2, the AI server featuring AMD Inst
DOCOMO and NEC to Establish “OREX SAI” Joint Venture to Provide OREX Packages for Open RAN Global Deployments26.2.2024 09:05:00 CET | Press release
NTT DOCOMO, INC. and NEC Corporation announced today that they plan to establish a joint venture company, OREX SAI, INC. on April 1 to provide OREX Packages solutions for the full-scale global deployment of Open RAN services. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240226531069/en/ Overview of OREX SAI (Graphic: Business Wire) OREX SAI will locally source products and services from members of OREX PARTNERS in each market and perform system verifications to deliver mobile networks tailored to the needs of each overseas telecommunications operator. Leveraging NEC’s established business infrastructure and global network in over 50 countries and territories, the joint venture will accelerate its global expansion of Open RAN business. In addition, DOCOMO and NEC plan to strengthen cooperation with OREX PARTNERS through OREX SAI to promote the commercialization and realization of true Open RAN that enables the interoperabil
Quectel introduces new ultra-low latency Wi-Fi 7 modules for PC OEMs26.2.2024 09:00:00 CET | Press release
MWC - Quectel Wireless Solutions, a global IoT solutions provider, has unveiled a new portfolio of Wi-Fi 7 modules that are ideal for PC OEMs looking to support Wi-Fi 7 in their devices’ connectivity technology options. The expanded Quectel Wi-Fi 7 and Bluetooth 5.4 modules range includes the Quectel NCM825, NCM825A, NCM835, NCM865 and NCM865A. All of the new modules offer support for Intel and AMD x86 platforms as well as the Snapdragon® X Elite platform for leading Windows PC experiences. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240226076383/en/ Quectel introduces new ultra-low latency Wi-Fi 7 modules for PC OEMs (Photo: Business Wire) The Quectel NCM825, NCM835 and NCM865 series modules utilize a Qualcomm® FastConnect™ 7800 Mobile Connectivity system from Qualcomm Technologies and support simultaneous operation on the 2.4GHz plus 5GHz and 2.4GHz plus 6 GHz frequency bands thanks to 2 x 2 MIMO with dual band simultan
PK MED Announces FDA Clearance to Initiate Its Clinical Program for PKM-01, for Local Treatment of Gout Flares, Directly by a Phase 2 Trial26.2.2024 09:00:00 CET | Press release
PK MED, a biotechnology company developing injectable smart implants for drug release in rheumatology and cell homing for bone marrow transplantation, today announced a significant potential breakthrough in the fight against gout, a form of arthritis that is widespread throughout the world. During a Type B pre-IND meeting1, the Food and Drug Administration gave its clearance to directly initiate the clinical program for PKM-01 with a phase 2 trial for gout patients, without undertaking phase 1 studies.PKM-01 is a local intra-articular injection treatment for gout flares, developed by PK MED, aiming to provide a fast an effective pain relief and powerful and safe anti-inflammatory effect. Thanks to its low-risk toxicity profile, PKM-01's clinical program will start directly in phase 2, which should considerably speed up time-to-market. Gout is characterized by repeated intense inflammatory acute episodes and excruciating pain, called gout flares, due to deposits of uric acid microcrysta